129 related articles for article (PubMed ID: 32456793)
1. AKT drives sustained motility following MEK inhibition via promoting SNAIL and AXL in MDA-MB-231 LM2.
Kwon J; Helfman DM; Kim MY
Biochem Biophys Res Commun; 2020 Jul; 528(1):92-98. PubMed ID: 32456793
[TBL] [Abstract][Full Text] [Related]
2. Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer.
Choi C; Kwon J; Lim S; Helfman DM
Oncotarget; 2016 Sep; 7(39):63466-63487. PubMed ID: 27563827
[TBL] [Abstract][Full Text] [Related]
3. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
Aksamitiene E; Kholodenko BN; Kolch W; Hoek JB; Kiyatkin A
Cell Signal; 2010 Sep; 22(9):1369-78. PubMed ID: 20471474
[TBL] [Abstract][Full Text] [Related]
4. Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression.
Henderson V; Smith B; Burton LJ; Randle D; Morris M; Odero-Marah VA
Cell Adh Migr; 2015; 9(4):255-64. PubMed ID: 26207671
[TBL] [Abstract][Full Text] [Related]
5. MEK/ERK and PI3K/AKT pathway inhibitors affect the transformation of myelodysplastic syndrome into acute myeloid leukemia via H3K27me3 methylases and de‑methylases.
Zheng Z; Chen X; Zhang Y; Ren F; Ma Y
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37921060
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-34a inhibits cell invasion and epithelial-mesenchymal transition via targeting AXL/PI3K/AKT/Snail signaling in nasopharyngeal carcinoma.
Jiang C; Cheng Z; Jiang T; Xu Y; Wang B
Genes Genomics; 2020 Aug; 42(8):971-978. PubMed ID: 32648233
[TBL] [Abstract][Full Text] [Related]
7. Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma.
Li Y; Jia L; Ren D; Liu C; Gong Y; Wang N; Zhang X; Zhao Y
IUBMB Life; 2014 Jul; 66(7):507-18. PubMed ID: 24984960
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
9. The Ras-ERK pathway modulates cytoskeleton organization, cell motility and lung metastasis signature genes in MDA-MB-231 LM2.
Choi C; Helfman DM
Oncogene; 2014 Jul; 33(28):3668-76. PubMed ID: 23995792
[TBL] [Abstract][Full Text] [Related]
10. Qigesan reduces the motility of esophageal cancer cells via inhibiting Gas6/Axl and NF-κB expression.
Kong L; Wu Z; Zhao Y; Lu X; Shi H; Liu S; Li J
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31110076
[TBL] [Abstract][Full Text] [Related]
11. PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation.
Jang K; Kim M; Seo HS; Shin I
Oncol Rep; 2010 Sep; 24(3):787-93. PubMed ID: 20664988
[TBL] [Abstract][Full Text] [Related]
12. Gas6 attenuates lipopolysaccharide‑induced TNF‑α expression and apoptosis in H9C2 cells through NF‑κB and MAPK inhibition via the Axl/PI3K/Akt pathway.
Li M; Ye J; Zhao G; Hong G; Hu X; Cao K; Wu Y; Lu Z
Int J Mol Med; 2019 Sep; 44(3):982-994. PubMed ID: 31524235
[TBL] [Abstract][Full Text] [Related]
13. Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells.
Tian Y; Zhang Z; Miao L; Yang Z; Yang J; Wang Y; Qian D; Cai H; Wang Y
Oncol Res; 2016; 24(5):295-303. PubMed ID: 27712586
[TBL] [Abstract][Full Text] [Related]
14. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
[No Abstract] [Full Text] [Related]
15. MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701.
Chen CH; Hsia TC; Yeh MH; Chen TW; Chen YJ; Chen JT; Wei YL; Tu CY; Huang WC
Mol Oncol; 2017 Sep; 11(9):1273-1287. PubMed ID: 28632938
[TBL] [Abstract][Full Text] [Related]
16. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
[TBL] [Abstract][Full Text] [Related]
18. Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells.
Kwon DS; Kwon CH; Kim JH; Woo JS; Jung JS; Kim YK
Eur J Cell Biol; 2006 Nov; 85(11):1189-99. PubMed ID: 16860436
[TBL] [Abstract][Full Text] [Related]
19. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
[TBL] [Abstract][Full Text] [Related]
20. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.
Turke AB; Song Y; Costa C; Cook R; Arteaga CL; Asara JM; Engelman JA
Cancer Res; 2012 Jul; 72(13):3228-37. PubMed ID: 22552284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
